Turning Point looks to challenge Pfizer, Roche with new early data for lead lung cancer drug

Turning Point Therapeutics shared a Phase I/II update for its lead drug candidate repotrectinib, but investors said they were expecting slightly better.

In 71 total TKI-naive patients, the confirmed objective response rate (cORR) to repotrectinib, also known as TPX-0005, was 79%, down from an earlier report of a 91% ORR in 22 patients. In addition, four patients achieved complete response, Turning Point said in a press release.